ArticleMolecular and clinical oncology2025
Effective management of a diabetic patient with hormone-receptor-positive, HER2-negative metastatic breast cancer using nanosomal docetaxel lipid suspension for 12 cycles: A case report.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study reports a case of a 40-year-old diabetic female patient diagnosed with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) in July 2017 and admitted to Cancure Cancer Centre (Tiruchirappalli, India). Following initial surgery and adjuvant treatment with four cycles each of fluorouracil, doxorubicin, and Cyclophosphamide chemotherapy and paclitaxel, radiotherapy and tamoxifen, the patient developed multiple metastases to the liver, lung and bones 3 years later. Palliative treatment with nanosomal docetaxel lipid suspension (NDLS) was started, resulting in a partial response (PR) after six cycles. NDLS was continued for 12 cycles in total, with good tolerance and no serious adverse effects. The patient maintained a PR and was managed with maintenance leuprolide, letrozole and palbociclib. The patient developed disease progression and died in July 2024, leading to a progression-free survival of ~ two years and an overall survival of two years and six months. To the best of our knowledge, the present case is among the first to report the safety and efficacy of 12 cycles of NDLS in MBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.